JW (Cayman) Therapeutics Co. Ltd

03 NOV 2020

Co-founded by Juno Therapeutics and Wuxi AppTec, JW (Cayman) Therapeutics Co. Ltd (the “Company”) is a leading clinical and pre-clinical stage cell therapy company in China with an integrated platform focusing on developing, manufacturing and commercializing breakthrough cell-based immunotherapies for hematological cancers and solid tumors. 

The Company’s vision is to develop innovative cell therapies for the China market to transform the treatment of cancer for Chinese patients. Relma-cel, an anti-CD19 CAR-T therapy for relapsed or refractory (“r/r”) B-cell lymphoma, is expected to be the first CAR-T therapy to be approved as a Category 1 biologics product in China. The company has built a comprehensive and differentiated cell therapy pipeline covering both hematological cancers and solid tumors.


公司的願景是為中國市場開發創新的細胞治療手段,為中國癌症患者帶來革命性的新藥治療方式。Relma-cel是針對復發或難治(「r/r」)B細胞淋巴瘤的抗CD19 CAR-T療法,有望成為中國首個獲批一類生物製品CAR-T療法。公司已建立了涵蓋血液癌症及實體瘤的全面且差異化的細胞治療產品管線。